M238P cells were treated 72 h with BRAFi (Vemurafenib, 3 µM) or with a combination of BRAFi (Vemurafenib, 0.5 µM) and MEKi (Trametinib, 1 µM). Effect of BRAFi or BRAFi plus MEKi on MRTFA (D) nuclear translocation by immunofluorescence. Data are represented as scatter plot with mean ± SD (n≥30 cells per condition). Each point represents the nuclear/cytoplasm ratio. Mann-Whitney U test was used for statistical analysis. ***P≤0.001, ****P≤0.0001. Scale bar 40 μm. 